PURPOSE: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT) application. Preclinical and clinical results are described. METHODS: (90)Y and (177)Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabelled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumour-bearing pretargeted animal model. A pilot study was performed in a metastatic melanoma patient and dosimetry was estimated. RESULTS: High radiochemical purity (>99%) was routinely achieved with (90)Y or (177)Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both (90)Y- and (177)Lu-r-BHD were also prepared at higher specific activities. Radiolabelled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilised it against enzymatic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumour uptake was observed in the pretargeted animals. The patient study showed a total body clearance of approximately 85% in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumour uptake was rapid and the calculated dose to a 10-mm tumour lesion was approximately 12 mGy/MBq. CONCLUSION: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.
PURPOSE: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT) application. Preclinical and clinical results are described. METHODS: (90)Y and (177)Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabelled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumour-bearing pretargeted animal model. A pilot study was performed in a metastatic melanomapatient and dosimetry was estimated. RESULTS: High radiochemical purity (>99%) was routinely achieved with (90)Y or (177)Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both (90)Y- and (177)Lu-r-BHD were also prepared at higher specific activities. Radiolabelled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilised it against enzymatic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumour uptake was observed in the pretargeted animals. The patient study showed a total body clearance of approximately 85% in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumour uptake was rapid and the calculated dose to a 10-mm tumour lesion was approximately 12 mGy/MBq. CONCLUSION: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.
Authors: D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg Journal: Proc Natl Acad Sci U S A Date: 2000-02-15 Impact factor: 11.205
Authors: G Paganelli; P Magnani; F Zito; E Villa; F Sudati; L Lopalco; C Rossetti; M Malcovati; F Chiolerio; E Seccamani Journal: Cancer Res Date: 1991-11-01 Impact factor: 12.701
Authors: D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Brian B Kegley; Janna Quinn; Robert L Vessella Journal: Bioconjug Chem Date: 2004 May-Jun Impact factor: 4.774
Authors: Andres Forero; Paul L Weiden; Julie M Vose; Susan J Knox; Albert F LoBuglio; Jordan Hankins; Michael L Goris; Vincent J Picozzi; Don B Axworthy; Hazel B Breitz; Robert B Sims; Richard G Ghalie; Sui Shen; Ruby F Meredith Journal: Blood Date: 2004-03-02 Impact factor: 22.113
Authors: Giuseppina Sabatino; Marco Chinol; Giovanni Paganelli; Stefano Papi; Mario Chelli; Giuseppe Leone; Anna Maria Papini; Angelo De Luca; Mauro Ginanneschi Journal: J Med Chem Date: 2003-07-03 Impact factor: 7.446
Authors: Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-03 Impact factor: 9.236
Authors: Rita De Santis; Claudio Albertoni; Antonio Rosi; Barbara Leoni; Fiorella Petronzelli; Valeria D'Alessio; Eleonora Nucera; Giovanni Salvatori; Giovanni Paganelli; Antonio Verdoliva; Paolo Carminati; Carlo Antonio Nuzzolo Journal: J Biomed Biotechnol Date: 2010-01-10
Authors: Rita De Santis; Anna Maria Anastasi; Angela Pelliccia; Antonio Rosi; Claudio Albertoni; Antonio Verdoliva; Fiorella Petronzelli; Valeria D'Alessio; Serenella Serani; Carlo Antonio Nuzzolo Journal: PLoS One Date: 2011-06-20 Impact factor: 3.240
Authors: G Paganelli; C De Cicco; M E Ferrari; G McVie; G Pagani; M C Leonardi; M Cremonesi; A Ferrari; M Pacifici; A Di Dia; F Botta; R De Santis; V Galimberti; A Luini; R Orecchia; U Veronesi Journal: Ecancermedicalscience Date: 2010-11-01
Authors: Claudio Albertoni; Barbara Leoni; Antonio Rosi; Valeria D'Alessio; Valeria Carollo; Luigi Giusto Spagnoli; Cees van Echteld; Rita De Santis Journal: Cancer Biother Radiopharm Date: 2015-07-13 Impact factor: 3.099